Dr Anthony Yanni, senior vice president and global head of patient centricity at Astellas Pharma, returns to Health Innovators to continue his conversation with Healthware’s chief content o
In this instalment of Health Innovators, Paul Tunnah, Healthware’s chief content officer, sits down with Dr Anthony Yanni, senior vice president and global head of patient centricity at Ast
pharmaphorum’s Paul Tunnah talks to Anthony Yanni, newly appointed senior vice president & global head of patient centricity, Astellas, about why partnering with patients is the corners
The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia.
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio